CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders.
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+61-3-93891911
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$8.54 billion
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableOptionable
CSL (ASX:CSL) Frequently Asked Questions
What is CSL's stock symbol?
CSL trades on the ASX under the ticker symbol "CSL."
How often does CSL pay dividends? What is the dividend yield for CSL?
CSL declared a Final dividend on Friday, August 16th. Investors of record on Friday, October 11th will be given a dividend of 1.478 per share on Friday, October 11th. This represents a yield of 0.65%. The ex-dividend date is Tuesday, September 10th. View CSL's Dividend History.
Has CSL been receiving favorable news coverage?
News articles about CSL stock have trended negative recently, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. CSL earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for CSL.
Who are some of CSL's key competitors?
Some companies that are related to CSL include Cronos Group (CRON), MorphoSys (MOR), MorphoSys (MOR), BTG (BTG), Asterias Biotherapeutics (AST), Abcam (ABC), Genus (GNS), Polynovo (PNV), Clinuvel Pharmaceuticals (CUV), Concordia International (CXR), Mesoblast (MSB), Kodiak Sciences (KOD), Resverlogix (RVX), Neptune Wellness Solutions (NEPT) and Biotest (BIO).
What other stocks do shareholders of CSL own?
Who are CSL's key executives?
CSL's management team includes the folowing people:
- Mr. Paul R. Perreault, MD, CEO & Exec. Director (Age 62)
- Mr. David Mark Lamont ACA, BCom, Chief Financial Officer (Age 53)
- Dr. Robert Andrew Cuthbertson, Chief Scientific Officer & Director of R&D and Director (Age 64)
- Mr. Gregory Boss BS(Hons), J.D., Exec. VP of Legal & Group Gen. Counsel (Age 58)
- Ms. Elizabeth Walker, Exec. VP & Chief HR Officer (Age 49)
What is CSL's stock price today?
One share of CSL stock can currently be purchased for approximately A$235.02.
How big of a company is CSL?
What is CSL's official website?
How can I contact CSL?
CSL's mailing address is 45 Poplar Road,, Parkville, MELBOURNE, VIC 3052, Australia. The company can be reached via phone at +61-3-93891911.
MarketBeat Community Rating for CSL (ASX CSL)
MarketBeat's community ratings are surveys of what our community members think about CSL and other stocks. Vote "Outperform" if you believe CSL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CSL will underperform the S&P 500 over the long term. You may vote once every thirty days.
